<DOC>
	<DOCNO>NCT00061425</DOCNO>
	<brief_summary>The purpose trial determine safety 90Y-radiolabeled , humanize ( CDR-grafted ) form LL2 monoclonal antibody patient Non-Hodgkin 's lymphoma ( NHL ) different dose level .</brief_summary>
	<brief_title>Treatment Non-Hodgkin 's Lymphoma With 90Y-hLL2 IgG</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Inclusion : Histological cytological diagnosis Bcell lymphoma , fail least one regimen standard chemotherapy . ( All histological grade NHL eligible trial . ) Measureable via CT , least one lesion &gt; = 1.5cm one dimension . ( Splenic tumor absence tumor qualify . ) Radiological study ( ie CT ) must perform within 4 week prior study start . Acceptable tumor burden allow adequate followup evaluation . Less 25 % bone marrow involvement , determine bone marrow biopsy . Must observe follow washout period : At least 4 week beyond major surgery . At least 4 week beyond radiation therapy index lesion , recover radiationinduced toxicity . At least 4 week beyond chemotherapy and/or immunotherapy . At least 2 week beyond corticosteriod ( ) use blood count laboratory criterion . Must Karnofsky score &gt; 70 % ( equivalent , ECOG 02 ) expect survival least 6 month . Serum creatinine &lt; = 1.5mg/dl creatinine clearance &gt; = 50ml/min . Serum bilirubin &lt; = 2mg/dl . Hemoglobin &gt; = 10 g/dl ; WBC &gt; = 3000/mm3 ; granulocyte count &gt; = 150/mm3 ; platelet count &gt; = 100,000/mm3 transfusion cytokine least 30 day prior study . Immunomedics ELISA assay HahLL2 &lt; 100ng/ml prior history monoclonal antibody infusion . Cognizant inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>NHL</keyword>
	<keyword>recurrent B-cell lymphoma</keyword>
</DOC>